Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Mike Ankley who wrote (3360)	7/18/1998 4:13:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 5,214,214 Perfluoro branched alkyl ethers and emulsions patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. Abstract ------------------------------------------------------------------------ There is provided a novel perfluorochemical represented by the formula, ##STR1## wherein R(F) is a perfluoroalkyl group, a perfluoro alkoxyalkyl group or a perfluoroalkyloxy group, X and X' are same as or different from each other and are a fluorine atom or a perfluoroalkyl group, and Y is a perfluoroalkyloxy group or a perfluoro dialkylamino group, the total number of the carbon atoms contained being an integer of 8 to 11 inclusive. The perfluorochemical is prepared by perfluorinating the corresponding partially fluorinated compound which may have unsaturated hydrocarbon moiety, only with molecular fluorine in a stoichiometric excess amount in an inert solvent. The perfluorochemical is used for preparing a stable emulsion as blood substitutes or perfusion media. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:17:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,943,595 Perfluorochemicals and process for preparing the same patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. Abstract ------------------------------------------------------------------------ There is provided a novel perfluorochemical represented by the formula, ##STR1## wherein R(F) is a perfluoroalkyl group, a perfluoro alkoxyalkyl group or a perfluoroalkyloxy group, X and X' are same as or different from each other and are a fluorine atom or a perfluoroalkyl group, and Y is a perfluoroalkyloxy group or a perfluoro dialkylamino group, the total number of the carbon atoms contained being an integer of 8 to 11 inclusive. The perfluorochemical is prepared by perfluorinating the corresponding partially fluorinated compound which may have unsaturated hydrocarbon moiety, only with molecular fluorine in a stoichiometric excess amount in an inert solvent. The perfluorochemical is used for preparing a stable emulsion as blood substitutes or perfusion media. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:19:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,868,318 Perfluoro chemicals and polyfluorinated compounds patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. Abstract ------------------------------------------------------------------------ The present invention relates to novel perfluoro chemicals (PFC), particularly perfluorocyclic ethers and polyfluorinated compounds containing a few chlorine atoms and to a method for the preparation thereof. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:26:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,713,459 Perfluoro compounds patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. Abstract ------------------------------------------------------------------------ A novel compound of the formula, ##STR1## wherein R denotes a lower perfluoroalkyl group, l is an integer of 3 or 4, n+m is an integer of 2 or 3, provided that n may be zero, and at least one of ring A and ring B may be substituted by a lower perfluoroalkyl group, prepared by reacting the corresponding perhydro compound with fluorine is useful as a material capable of carrying oxygen in an aqueous emulsion for lifesaving a patient suffering from massive hemorrhage and for preserving internal organs in transplantation. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:29:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,686,024 Novel perfluoro chemicals and polyfluorinated compounds and process for production of the same patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. Abstract ------------------------------------------------------------------------ The present invention relates to novel perfluoro chemicals (PFC), particularly perfluorocyclic ethers and polyfluorinated compounds containing a few chlorine atoms and to a method for the preparation thereof. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:31:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,613,605 Perfluoro-1-azatricyclic amines as blood substitutes patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ A novel compound of the formula, ##STR1## wherein k is zero or an integer of 1 to 2, j is an integer of from 1 or 3, l and m are each zero or an integer of from 1 to 3, and n is an integer of from 1 to 4, the rings A, B and C being optionally substituted with at least one trifluoromethyl group or tetrafluoroethyl group is prepared by reacting the perhydro compound corresponding thereto with fluorine. The compound is useful as a material capable of carrying oxygen in an aqueous emulsion for lifesaving a patient suffering from massive hemorrhage and for preserving internal organs in transplantation. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:38:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,605,786 Perfluoro ether compound containing perfluorocycloalkyl moiety patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ A perfluoroether compound having the following formula is useful as a thermostable, inert solvent and inter alia as an oxygen carrier in an artificial blood or infusion fluid. ##STR1## wherein Rf(1) and Rf(2) are different from each other and are selected from the group of a C(1) or C(3) perfluoroalkyl group which may be interrupted by an oxygen atom, and a C(5) -C(7) perfluorocycloalkyl group, and n and n' are zero or an integer of 1; one of Rf(1) and Rf(2) being the C(5) -C(7) perfluorocycloalkyl group and the total number of carbon atoms being 9-11 inclusive. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:41:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,605,650 Perfluoro-1-azatricyclic amine compounds useful as oxygen carriers in artificial blood and infusion fluids patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ A novel compound of the formula, ##STR1## wherein k is zero or an integer of 1 to 2, j is an integer of from 1 to 3, l and m are each zero or an integer of from 1 to 3, and n is an integer of from 1 to 4, the rings A, B and C being optionally substituted with at least one trifluoromethyl group or tetrafluoroethyl group is prepared by reacting the perhydro compound corresponding thereto with fluorine. The compound is useful as a material capable of carrying oxygen in an aqueous emulsion for lifesaving a patient suffering from massive hemorrhage and for preserving internal organs in transplantation. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:43:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,599,343 Perfluoroindolizines and emulsions thereof useful as blood substitutes patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ A perfluorobicyclo compound of the general formula: ##STR1## wherein either or both of Ring A and Ring B may optionally be substituted with lower perfluoroalkyl group(s) and m and n each represent 3 or 4. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:45:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,596,810 Emulsions of perfluoro octahydro quinolizines useful as blood substitutes patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ A perfluorobicyclo compound of the general formula: ##STR1## wherein either or both of Ring A and Ring B may optionally be substituted with lower perfluoroalkyl group(s) and m and n each represent 3 or 4. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:47:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,591,593 Perfluoro compound and emulsion thereof patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ A novel compound of the formula, ##STR1## wherein R denotes a lower perfluoroalkyl group l is an integer of 3 or 4, n+m is an integer of 2 or 3, provided that n may be zero, and at least one of ring A and ring B may be substituted by a lower perfluoroalkyl group, prepared by reacting the corresponding perhydro compound with fluorine is useful as a material capable of carrying oxygen in an aqueous emulsion for lifesaving a patient suffering from massive hemorrhage and for preserving internal organs in transplantation. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:49:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,535,085 Perfluorotricyclic amines as oxygen carriers patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ A perfluorotricyclic amine compound which is usable as an oxygen carrier in an artificial blood, represented by the general formula ##STR1## wherein R denotes a perfluoroalkyl group having 1-4 carbon atoms; the ring A denotes a five- or six-membered ring, the ring B denotes a five-, six- or seven-membered ring, the ring C denotes a five- or six-membered ring any one of the rings A, B and C optionary being substituted by one or more lower perfluoroalkyl group in addition to the above-mentioned substituent R; and further f, g, h, i, j and k denote integers appropriately selected to construct the above-mentioned size of rings A, B, and C; is prepared by reacting the corresponding perhydrotricyclic amine with fluorine. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:51:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,530,926 Perfluorotricyclic amines as oxygen carriers patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ A novel compound of the formula, ##STR1## wherein k, j, l and m are zero or an integer of from 1 to 3, and n is an integer of from 1 to 3, the rings A, B and C being optionally substituted with at least one trifluoromethyl group, prepared by reacting the corresponding perhydro compound with fluorine is useful as a material capable of carrying oxygen in an aqueous emulsion for lifesaving a patient suffering from massive hemorrhage and for preserving internal organs in transplantation. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:54:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,425,347 Perfluorobicyclo compound emulsion preparation patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ A perfluorobicyclo compound emulsion preparation having oxygen carrying ability containing a perfluorobicyclo compound of the general formula: ##STR1## wherein R represents a perfluoromethyl group or perfluoroethyl group, as an oxygen carrying component. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 4:57:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,423,061 Perfluorocycloamine emulsion preparation patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ A perfluorocycloamine emulsion preparation having oxygen carrying ability containing a perfluorocycloamine of the general formula: ##STR1## wherein any position may optionally be substituted with a perfluoromethyl group as an oxygen carrying component. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 5:00:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,252,827 Oxygen-transferable fluorocarbon emulsion patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ 50-95 Parts by weight of a perfluorocarbon compound such as perfluorodecalin, perfluoromethyldecalin, perfluoro alkylcyclohexanes having 3 to 5 carbon atoms in the alkyl, perfluoro alkyltetrahydrofurans having 5 to 7 carbon atoms in the alkyl, perfluoro alkyltetrahydropyrans having 4 to 6 carbon atoms in the alkyl, perfluoroalkanes having 9 to 11 carbon atoms, and 50-5 parts by weight of a perfluoro tert.-amine such as perfluoro tert.-alkylamines having 9-11 carbon atoms, perfluoro N-alkylpiperidines having 4 to 6 carbon atoms in the alkyl, and perfluoro N-alkylmorpholines having 5 to 7 carbon atoms in the alkyl are emulsified in an aqueous medium by the aid of a high-molecular-weight nonionic surfactant have a molecular weight of about 2,000 to 20,000, and phospholipids as emulsifying agent, and fatty acids having 8 to 22 carbon atoms or salts or monoglycerides thereof as emulsifying adjuvant. The resulting oxygen-transferable emulsion having a particle size of 0.05 to 0.25mu is very stable for a long period of time, can be mixed with plasma extenders, and retains for long time in the blood stream of animals when it is used as an artificial blood substitute while being excreted very rapidly. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 5:02:00 AM
From: Mike Ankley	Respond to of 5402

Green Cross assigned U.S. patent 4,186,253 Perfusate for preserving organ to be transplanted and preserving method patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ An organ to be transplanted, such as kidney, can effectively be preserved by perfusion for a considerably long time by the use of a perfusate which is made by mixing a Ringer's solution modified by increasing potassium ion to 8-20 meq/l, a stable perfluorocarbon compound emulsion and albumin, so that the concentration of the perfluorocarbon compound is 7.5 to 12.5% (W/V) and that of albumin is 1-8% (W/V) based on the perfusate. Cheers Mike

To: Mike Ankley who wrote (3360)	7/18/1998 5:03:00 AM
From: Mike Ankley	Read Replies (1) \| Respond to of 5402

Green Cross assigned U.S. patent 3,962,439 Oxygen-transferable emulsion patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ Oxygen-transferable perfluorocarbon compounds having 9 to 11 carbon atoms such as perfluorodecalin, perfluoro(C(3-5) -alkylcyclohexanes), perfluoro(C(4-6) -alkyl tetrahydropyrans), perfluoro(C(5-7) -alkyltetrahydrofurans), perfluoro(C(5-7) -alkylmorpholins) and perfluoro(C(9-11) -trialkylamines) are emulsified in a physiologically acceptable aqueons solution such as Ringer's solution by the aid of a phospholipid as emulsifier and a fatty acid of 8 to 22 carbon atoms, alkali metal salt or monoglyceride thereof as emulsifying adjuvant. The emulsion is stable for a considerable period of time and contains particles having a particle size ranging from 0.05 to 0.3 mu. It is usable as a blood substitute or a perfusate for preservation of the internal organs. Cheers Mike